| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Lotusine hydroxide targets ion channels in the myocardium. It has an effect on the action potential in the myocardium and the slow inward current of cardiac Purkinje fibers. This cardiovascular activity suggests it may modulate cardiac ion channels, though the specific molecular target is not fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Lotusine hydroxide affects the action potential in the myocardium and the slow inward current of cardiac Purkinje fibers. This indicates it modulates cardiac ion channel activity. However, specific IC50 values and detailed in vitro activity data are not extensively reported.
|
| ln Vivo |
In vivo, Lotusine hydroxide exhibits cardiovascular activity. However, specific in vivo efficacy data and detailed animal study results are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro electrophysiological assays for Lotusine hydroxide involve measuring its effects on action potentials and ion currents in cardiac Purkinje fibers or myocardial cells. Patch-clamp techniques can be used to record changes in ion channel activity in the presence of the compound.
|
| Cell Assay |
In vitro cellular assays for Lotusine hydroxide are performed using cardiac myocytes or Purkinje fibers to study its effects on action potentials and ion currents. Cells are treated with various concentrations of the compound, and electrophysiological recordings are made.
|
| Animal Protocol |
In vivo animal studies with Lotusine hydroxide would typically be conducted in animal models to assess its cardiovascular effects. However, specific protocols are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Lotusine hydroxide are not extensively reported. It has a molecular weight of 331.41 and is typically stored as a powder at -20°C for up to 3 years. Specific parameters such as oral bioavailability, half-life, and tissue distribution are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Lotusine hydroxide is not extensively reported. As a research compound, it is for research use only and not for human therapeutic use. No specific toxicity data are detailed.
|
| References | |
| Additional Infomation |
Lotusine hydroxide (CAS 3721-76-4) is a pure quaternary alkaloid isolated from the green embryo of Nelumbo nucifera Gaertn (lotus). It has a molecular formula of C19H25NO4 and a molecular weight of 331.41. The compound affects cardiac action potentials and ion currents and is used in cardiovascular research. It is available for research purposes only.
|
| Molecular Formula |
C19H25NO4
|
|---|---|
| Molecular Weight |
331.41
|
| Exact Mass |
331.178
|
| CAS # |
3721-76-4
|
| Related CAS # |
Lotusine;6871-67-6
|
| PubChem CID |
168008606
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
392
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1(=C(OC)C=C2C(=C1)CC[N+](C)(C)[C@@H]2CC1C=CC(O)=CC=1)O.[OH-]
|
| InChi Key |
WGTLSSKYFYKCNF-UNTBIKODSA-N
|
| InChi Code |
InChI=1S/C19H23NO3.H2O/c1-20(2)9-8-14-11-18(22)19(23-3)12-16(14)17(20)10-13-4-6-15(21)7-5-13;/h4-7,11-12,17H,8-10H2,1-3H3,(H-,21,22);1H2/t17-;/m1./s1
|
| Chemical Name |
(1R)-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1H-isoquinolin-2-ium-6-ol;hydroxide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0174 mL | 15.0871 mL | 30.1741 mL | |
| 5 mM | 0.6035 mL | 3.0174 mL | 6.0348 mL | |
| 10 mM | 0.3017 mL | 1.5087 mL | 3.0174 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
